Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
COVID-19 발생 시 류마티스 질환에 대한 생물학적 제제: 친구 또는 적?
Observational Study
[키워드] affected
age
analysed
Autoimmunity
Baricitinib
Biological agent
biological therapy
cardiovascular disease
Care
Community
Comorbidities
covariate
COVID-19
COVID-19 infection
cytokine production
determine
diagnosed
diagnosed with COVID-19
Diagnosis
disease
dose
drug
Epidemiology
exacerbated
form
General population
glucocorticoid
group
hospital
Hospital admission
hospitalisation
hypertension
IL-1
IL-6
IL-6 inhibitor
IL-6 inhibitors
immunosuppressed patient
incidence of COVID-19
incidence rate
Inflammation
Inflammatory
inhibitor
inhibitors
intensive care
IQR
JAK inhibitor
less
lowest
management
manifestation
median age
multivariate logistic regression
no difference
no significant difference
occur
Older
outbreak
outpatient clinic
Patient
patients
patients died
patients treated
patients with COVID-19
performed
positive
prognosis of patient
proportions
Protective
protective effect
protective factor
raised
receiving
required
retrospective
rheumatic disease
Rheumatic diseases
rheumatological
rheumatology
risk
risk factor
sarilumab
SARS-CoV-2
severe COVID-19 disease
Sex
smoker
Spain
suggested
tested
therapy
Tocilizumab
Treatment
with COVID-19
[DOI] 10.1136/rmdopen-2020-001439 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1136/rmdopen-2020-001439 PMC 바로가기 [Article Type] Observational Study